Activated Wnt/β-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 4, 2009, Pages 1193-1198

  Chien, Andy J ^a   Moore, Erin C ^a,b   Lonsdorf, Anke S ^c   Kulikauskas, Rima M ^a   Rothberg, Bonnie Gould ^d   Berger, Aaron J ^d   Major, Michael B ^a,b   Hwang, Sam T ^c   Rimm, David L ^d   Moon, Randall T ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B16 model; Differentiation; Metastasis; Microarray; Prognosis; WNT5A

Indexed keywords

BETA CATENIN; WNT PROTEIN; WNT3A PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; METASTASIS; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; UPREGULATION;

ANIMALS; BETA CATENIN; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL LINEAGE; CELL NUCLEUS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; MELANOCYTES; MELANOMA, EXPERIMENTAL; MICE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SURVIVAL ANALYSIS; UP-REGULATION; WNT PROTEINS;

MURINAE; MUS;

EID: 59049101982     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0811902106     Document Type: Article

References (53)

1. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998-1012.
2. Weeraratna AT (2005) A Wnt-er wonderland: The complexity of Wnt signaling in melanoma. Cancer Metastasis Rev 24:237-250.
3. Chien AJ, Moon RT (2007) WNTS and WNT receptors as therapeutic tools and targets in human disease processes. Front Biosci 12:448-457.
4. Weidinger G, Moon RT (2003) When Wnts antagonize Wnts. J Cell Biol 162:753-755.
5. Veeman MT, Axelrod JD, Moon RT (2003) A second canon: Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell 5:367-377.
6. Rivera MN, et al. (2007) An X chromosome gene, WTX, is commonly inactivated in Wilms' tumor. Science 315:642-645.
7. Major MB, et al. (2007) Wilms' tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 316:1043-1046.
8. Koesters R, et al. (1999) Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 59:3880-3882.
9. Giles RH, van Es JH, Clevers H (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653:1-24.
10. Rijsewijk F, et al. (1987) The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 50:649-657.
11. Lugli A, et al. (2007) Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: A tissue microarray-based analysis. Histopathology 50:453-464.
12. Wong SC, Lo ES, Lee KC, Chan JK, Hsiao WL (2004) Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 10:1401-1408.
13. Miyamoto S, et al. (2004) Nuclear beta-catenin accumulation as a prognostic factor in Dukes' D human colorectal cancers. Oncol Rep 12:245-251.
14. Cheah PY, Choo PH, Yao J, Eu KW, Seow-Choen F (2002) A survival-stratification model of human colorectal carcinomas with beta-catenin and p27kip1. Cancer 95:2479-2486.
15. Omholt K, Platz A, Ringborg U, Hansson J (2001) Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int J Cancer 92:839-842.
16. Pollock PM, Hayward N (2002) Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines. Melanoma Res 12:183-186.
17. Reifenberger J, et al. (2002) Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int J Cancer 100:549-556.
18. Rubinfeld B, et al. (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275:1790-1792.
19. Worm J, Christensen C, Gronbaek K, Tulchinsky E, Guldberg P (2004) Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 23:5215-5226.
20. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER (1999) Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 154:325-329.
21. Weeraratna AT, et al. (2002) Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1:279-288.
22. Weeraratna AT, et al. (2004) Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene 23:2264-2274.
23. Da Forno PD, et al. (2008) WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res 14:5825-5832.
24. Bittner M, et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536-540.
25. Crane JF, Trainor PA (2006) Neural crest stem and progenitor cells. Annu Rev Cell Dev Biol 22:267-286.
26. Vance KW, Goding CR (2004) The transcription network regulating melanocyte development and melanoma. Pigment Cell Res 17:318-325.
27. Larue L, Kumasaka M, Goding CR (2003) Beta-catenin in the melanocyte lineage. Pigment Cell Res 16:312-317.
28. Dorsky RI, Raible DW, Moon RT (2000) Direct regulation of nacre, a zebrafish MITF homolog required for pigment cell formation, by the Wnt pathway. Genes Dev 14:158-162.
29. Bachmann IM, StraumeO, Puntervoll HE, Kalvenes MB, Akslen LA (2005) Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 11:8606-8614.
30. Kageshita T, et al. (2001) Loss of beta-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol 145:210-216.
31. Maelandsmo GM, Holm R, Nesland JM, Fodstad O, Florenes VA (2003) Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res 9:3383-3388.
32. Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8:1323-1327.
33. Thompson JA (2002) The revised American Joint Committee on Cancer staging system for melanoma. Semin Oncol 29:361-369.
34. Fang D, et al. (2006) Defining the conditions for the generation of melanocytes from human embryonic stem cells. Stem Cells 24:1668-1677.
35. Jho EH, et al. (2002) Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22:1172-1183.
36. Moon RT, Kohn AD, De Ferrari GV, Kaykas A (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5:691-701.
37. Roose J, et al. (1999) Synergy between tumor-suppressor APC and the beta-catenin-Tcf4 target Tcf1. Science 285:1923-1926.
38. Watabe K, et al. (2001) Structure, expression and chromosome mapping of MLZE, a novel gene which is preferentially expressed in metastatic melanoma cells. Jpn J Cancer Res 92:140-151.
39. Bilalovic N, et al. (2004) CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod Pathol 17:1251-1258.
40. Loftus SK, et al. (1999) Informatic selection of a neural crest-melanocyte cDNA set for microarray analysis. Proc Natl Acad Sci U S A 96:9277-9280.
41. Witze ES, Litman ES, Argast GM, Moon RT, Ahn NG (2008) Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors. Science 320:365-369.
42. Dissanayake SK, et al. (2007) The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial-to-mesenchymal transition. J Biol Chem 282:17259-17271.
43. Widlund HR, et al. (2002) Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol 158:1079-1087.
44. Delmas V, et al. (2007) Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 21:2923-2935.
45. Ryu B, Kim DS, Deluca AM, Alani RM (2007) Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS ONE 2:e594.
46. Duncan LM, et al. (2001) Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 19:568-576.
47. Duncan LM, et al. (1998) Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 58:1515-1520.
48. Hammock L, et al. (2006) Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma. J Cutan Pathol 33:599-607.
49. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ (2006) Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res 66:7833-7836.
50. Zabierowski SE, Herlyn M (2008) Melanoma stem cells: The dark seed of melanoma. J Clin Oncol 26:2890-2894.
51. Murakami T, et al. (2002) Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 62:7328-7334.
52. Dull T, et al. (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463-8471.
53. Kreizenbeck GM, Berger AJ, Subtil A, Rimm DL, Gould Rothberg BE (2008) Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 17:949-958.